港股异动 | 生物医药板块持续走高,再鼎医药绩后涨超12%,康方生物涨近5%

老虎资讯综合
28 Mar

本周五(3月28日)港股盘初,生物医药板块持续走高,截至发稿 再鼎医药 绩后涨超12%, 康方生物 涨近5%:

消息面上,3月28日,再鼎医药发布截至2024年12月31日止年度年度业绩,总收入3.99亿美元,同比增加49.59%;研发开支2.35亿美元。

公告称,收入增长主要是由于卫伟迦自2023年9月强势商业化上市并于2024年1月首次被纳入国家医保目录以来其销售额稳步增长;则乐继续保持卵巢癌领域PARP抑制剂院内销售领军者地位;以及得益于纽再乐用于治疗CABP及╱或ABSSSI的静脉注射剂型及用于该等适应证的口服剂型分别于2023年1月及2024年1月被纳入国家医保目录。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10